CTAS vs STRO · P/E 51, rev $10.34B vs rev $62.0M
Cintas Corporation (CTAS) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CTAS and STRO stock pages for the full models.
Not investment advice.